Intracellular bevacizumab reduces phagocytotic uptake in RPE cells

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 248, Issue 6, 2010, Pages 819-824

  Klettner, Alexa ^a   Möhle, Friederike ^a   Roider, Johann ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Age related macular degeneration; Bevacizumab; Phagocytosis; Ranibizumab

Indexed keywords

BEVACIZUMAB; FLUORESCEIN ISOTHIOCYANATE; RANIBIZUMAB;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL FUNCTION; CELL LEVEL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG UPTAKE; EPITHELIUM CELL; IN VITRO STUDY; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PHOTORECEPTOR OUTER SEGMENT; PIGMENT EPITHELIUM; PRIORITY JOURNAL; SWINE; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL PROLIFERATION; CELLS, CULTURED; PHAGOCYTOSIS; RETINAL PHOTORECEPTOR CELL OUTER SEGMENT; RETINAL PIGMENT EPITHELIUM; SWINE; WOUND HEALING;

EID: 77952099468     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-010-1317-x     Document Type: Article

References (29)

1. RO Schlingemann AN Witmer 2009 Treatment of retinal diseases with VEGF antagonists Prog Brain Res 175 253 267 10.1016/S0079-6123(09)17517-9 1:CAS:528:DC%2BD1MXhsVeht7jE 19660661
2. PV Agvere A Kvanta S Seregard 2008 Shall we use Avastin or Lucentis for ocular neovascularisation? Acta Ophthalmol 86 352 355 10.1111/j.1755-3768.2008. 01317.x
3. RM Klein RP Klein 2007 Avastin versus Lucentis: ethical issues in treatment of AMD Retina 27 1163 1165 10.1097/IAE.0b013e31815e9322 18046218 (Pubitemid 350211518)
4. F Ziemssen S Grisanti KU Bartz-Schmidt MS Spitzer 2009 Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? Drugs Aging 26 295 320 10.2165/00002512-200926040-00002 1:CAS:528:DC%2BD1MXosFSlsL4%3D 19476398
5. SS Lynch CM Cheng 2007 Bevacizumab for neovascular ocular disease Ann Pharmacother 41 614 625 10.1345/aph.1H316 1:CAS:528:DC%2BD2sXltlOnsrs%3D 17355998 (Pubitemid 46625484)
6. ZF Bashshur ZA Haddad AR Schakal RF Jaafar A Saad BN Noureddin 2009 Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study Am J Ophthalmol 148 59 65 10.1016/j.ajo.2009.02.006 1:CAS:528:DC%2BD1MXnsV2ru7k%3D 19375689
7. S Mennel J Callizo JC Schmidt CH Meyer 2007 Acute retinal pigment epithelial tear in the untreated eye following repeated bevacizumab (Avastin) injections Acta Ophthalmol Scand 85 689 691 10.1111/j.1600-0420.2007.00926.x 17403025 (Pubitemid 47316777)
8. S Peters P Heiduschka S Julien S Grisanti F Ziemssen M Adler U Schraermeyer KU Bartz-Schmidt 2007 Ultrastructural findings in the primate eye after intravitreal injections of bevacizumab Am J Ophthalmol 143 995 1002 10.1016/j.ajo.2007.03.007 1:CAS:528:DC%2BD2sXlvVakur4%3D 17449002 (Pubitemid 46764670)
9. ZL Huang KH Lin YC Lee MM Sheu RK Tsai 2008 Acute vision loss after intravitreal injection of Bevacizumab (Avastin) associated with ocular ischemic syndrome Ophthalmologica 224 86 89 10.1159/000235726
10. A Klettner J Roider 2008 Comparison of Bevacizumab, Ranibizumab and Pegaptanib in vitro: efficiency and possible additional pathways Invest Ophthalmol Vis Sci 49 4523 4527 10.1167/iovs.08-2055 18441313
11. A Klettner ML Kruse T Meyer D Wesch D Kabelitz J Roider 2009 Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells Graefes Arch Clin Exp Ophthalmol 247 1601 1608 10.1007/s00417-009- 1136-0 1:CAS:528:DC%2BD1MXhsVWntLrM 19597740
12. O Strauss 2005 The RPE in the visual function Physiol Rev 85 845 881 10.1152/physrev.00021.2004 1:CAS:528:DC%2BD2MXmsFymu7Y%3D 15987797 (Pubitemid 40885218)
13. DS Papermaster WJ Dreyer 1974 Rhodopsin content in the outer segment membranes of bovine and frog retinal rods Biochemistry 13 2438 2444 10.1021/bi00708a031 1:CAS:528:DyaE2cXksVKls74%3D 4545509
14. U Schraermeyer V Enzmann L Kohen K Addicks P Wiedermann K Heimann 1997 Porcine iris pigment epithelial cells can take up retinal outer segments Exp Eye Res 65 277 287 10.1006/exer.1997.0339 1:CAS:528:DyaK2sXls1Wqsr4%3D 9268596 (Pubitemid 27360158)
15. BE Steinberg S Grinstein 2003 Assessment of phagosome formation and maturation by fluorescence microscopy Methods Mol Biol 138 289 300
16. MS Spitzer E Yoeruek A Sierra B Wallenfels-Thilo U Schraermeyer B Spitzer KU Bartz-Schmidt P Szurman 2007 Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells Graefes Arch Clin Exp Ophthalmol 245 1837 1842 10.1007/s00417-007-0568-7 1:CAS:528:DC%2BD2sXhtlWrtrrN 17347807 (Pubitemid 350154019)
17. M Kernt U Welge-Lüen A Yu AS Neubauer A Kampik 2007 Bevacizumab wirkt nicht toxisch auf Zellen des menschlichen Auges Ophthalmologe 104 965 971 10.1007/s00347-007-1569-y 1:CAS:528:DC%2BD2sXhtlClsr3L 17653724
18. MOM Tso E Friedman 1968 The retinal pigment epithelium. III. Growth and development Arch Ophthalmol 80 214 216 1:STN:280:DyaF1czisFyisw%3D%3D
19. JF Kiilgaard JU Prause M Prause E Scherfig MH Nissen M la Cour 2007 Subretinal posterior pole injury induces selective proliferation of RPE cells in the periphery in in vivo studies in pigs Invest Ophthalmol Vis Sci 48 355 360 10.1167/iovs.05-1565 17197554 (Pubitemid 47251424)
20. H Al-Hussaini JH Kam A Vugler M Semo G Jeffery 2008 Mature retinal pigment epithelium cells are retained in the cell cycle and proliferate in vivo Mol Vis 14 1784 1791 1:CAS:528:DC%2BD1cXhtlSmurjJ 18843376
21. LV Del Priore YH Kuo TH Tezel 2002 Age-related changes in human RPE cell density and apoptosis proportion in situ Invest Ophthalmol Vis Sci 43 3312 3318 12356840
22. C Brostjan K Gebhardt B Gruenberger V Steinrueck H Zommer H Freudenthaler S Roka T Gruenberger 2008 Neoadjuvant treatment of colorectal cancer with bevacizumab: systemic thrombospondin-1 levels Clin Cancer Res 14 7 2065 2074 10.1158/1078-0432.CCR-07-4081 1:CAS:528:DC%2BD1cXkt1aku74%3D 18381946 (Pubitemid 351551117)
23. TC Verstraeten SM Buzney SG Macdonald AH Neufeld 1990 Retinal pigment epithelium wound closure in vitro Invest Ophthalmol Vis Sci 31 481 488 1:STN:280:DyaK3c3gt1alsw%3D%3D 2318587
24. J Roider NA Michaud TJ Flotte R Birngruber 1992 Response of the retinal pigment epithelium to selective photocoagulation Arch Ophthalmol 110 1786 1792 1:STN:280:DyaK3s%2FpvVOmuw%3D%3D 1463423
25. RA Weisman ED Korn 1967 Phagocytosis of latex beads by Acanthamoeba. I. Biochemical properties Biochemistry 6 485 497 10.1021/bi00854a017 1:CAS:528:DyaF2sXltlajtA%3D%3D 4860149
26. A Terman UT Brunk 2004 Aging as a catabolic malfunction Int J Biochem Cell Biol 36 2365 2375 10.1016/j.biocel.2004.03.009 1:CAS:528: DC%2BD2cXmvFemurY%3D 15325578 (Pubitemid 39119752)
27. K Sun H Cai TH Tezel TH Tezel D Paik ER Gaillard LV Del Priore 2007 Bruch's membrane aging decreases phagocytosis of outer segments by retinal pigment epithelium Mol Vis 12 2310 2319
28. C Vives-Bauza M Anand AK Shirazi J Magrane J Gao HR Vollmer-Snarr G Manfredi SC Finnemann 2008 The age lipid A2E and mitochondrial dysfunction synergistically impair phagocytosis by RPE cells J Biol Chem 283 24770 24780 10.1074/jbc.M800706200 1:CAS:528:DC%2BD1cXhtVGktbvF 18621729
29. PE Rakoczy D Zhang T Robertson NL Barnett J Papadimitriou IJ Constable CM Lai 2002 Progressive age-related changes similar to age related macular degeneration in a transgenic mouse model Am J Pathol 161 1515 1524 1:CAS:528:DC%2BD38Xotl2jt7k%3D 12368224